COPD Tutoring – Part 1 By Alaina Darby.

Slides:



Advertisements
Similar presentations
GOLD MANAGEMENT PLAN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Advertisements

New Therapeutic Options for COPD
Optimizing the Management of Chronic Obstructive Pulmonary Disease (COPD) Note to the Speaker: All bold underlined statements must be read aloud to the.
Michael W. Nash, MD Family Medicine Clinton County Rural Health Clinic Understanding COPD.
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Professor of Respiratory Medicine
COPD Mohammad Ruhal Ain R Ph, PGDPRA, M Pharm (Clin. Pharm)
CHRONIC OBSTRUCTIVE PULMONARY DISEASE Treatment Opportunities in a Heartsink Disease Jim Reid.
COPD (Chronic Obstructive Pulmonary Disease)
Management of Patients With Chronic Pulmonary Disease.
COPD MANAGEMENT FALLS SHORT AT RCRMC Jean Solomon, M.D.
COPD Joshua Jewell. Epidemiology 8% of all individuals 10% age >40 6 th leading cause of death worldwide th in U.S. - >120,000 Expected 3 rd 2020.
Chronic obstructive pulmonary disease (COPD) Professor Bill MacNee
Central Ohio Pulmonary Disease, Inc. Michael L. Corriveau, MD, FACP, FCCP.
COPD Management of Stable COPD Shyam Rao May 2014.
GOLD Website Address
Habib GHEDIRA, MD, Prof. Medical Faculty of Tunis
Daliresp (roflumilast) - Company: Forest Pharmaceuticals - Treatment for: chronic obstructive pulmonary disease (COPD). - First approved February 28th,
Matt Wong + Sheila Murphy Dec 13 th  AKT MINI EXAM  NICE – COPD GUIDELINES  BTS ASTHMA GUIDELINES  INHALER TECHNIQUE  QOF  SPIROMETRY  CSA.
يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11 بسم الله الرحمن الرحیم با سلام.
COPD – PBL 8. Hypercapnia (  CO 2 )Hypoxia (  O 2 ) HyperventilationDyspnoea AsterixisHeadaches/fatigue Flushed skinCynosis Disturbed sleepTachapneoa.
Chronic obstructive pulmonary disease Edited by Chien-Da Huang Physician Educator/Associate Professor Department of Thoracic Medicine and Medical Education.
COPD (Chronic Obstructive Pulmonary Disease)
GOLD Update 2011 Rabab A. El Wahsh, MD. Lecturer of Chest Diseases and Tuberculosis Minoufiya University REVISED 2011.
Andriy Lepyavko, MD, PhD Department of Internal Medicine № 2.
Chronic Obstructive Pulmonary Disease Austin Paul K.
Exacerbations. Exacerbations An exacerbation of COPD is an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond.
© IPCRG 2007 COPD -Management of stable disease WONCA meeting Istanbul October 2015 Svein Høegh Henrichsen Oslo, Norway.
Percent Change in Age-Adjusted Death Rates, U.S., Proportion of 1965 Rate –59% –64% –35% +163% –7% Coronary.
History Taking Zinc code: UKACL1878ea Date of preparation May 2015 AstraZeneca provided funding & reviewed for technical accuracy.
LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,
내과 R2 이지훈 N Engl J Med Sep 8.
Chronic Obstructive Pulmonary Disease 연세대학교 의과대학 응급의학교실 강사 조준호.
Prescribing for patients with COPD Evidence Update Emma Blanden- Pharmacist.
Chronic Obstructive Pulmonary Disease. COPD is an umbrella term for two diseases which cause progressive airflow obstruction Chronic Bronchitis- Inflammation.
ASTHMA Definition: Asthma is a chronic lung disease due to inflammation of the airways resulted into airway obstruction. The obstruction is reversible.
Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.
Clinical Applications of Spirometry for Pediatric Asthma
Azithromycin – for better or worse in chronic lung infection? Professor Emma Baker Professor of Clinical Pharmacology St George's, University of London.
Chronic Obstructive Pulmonary Disease Clinacal Pharmacy.
Obstructive lung disease
GOLD 2017 major revision: Summary of key changes
Current management of COPD and when to refer?
Respiratory Initiatives: GOLD - ABCD, CAT Scores and myCOPD
Pulmonary Center of Excellence
Chronic Obstructive Pulmonary Disease(COPD)
Pharmacology of Anti- Asthmatic Medications
COPD – Primary Care Update
Increased Exhaled Nitric Oxide and Risk of Loss of Control in Children Undergoing Clinical Asthma Remission   D.V. Chang, J.E. Balinotti, C. Castro Simonelli,
Management of Chronic Airflow Obstruction
Management of Severe Asthma and COPD
Management of Stable COPD
Therapeutics 2 Tutoring: Asthma
Chronic Obstructive Pulmonary Disease (COPD)
COPD Tutoring – Part 2 By Alaina Darby.
COPD By Alaina Darby.
COPD Dr MAMATHA SARTHI GPST3.
Difficult Cases: Asthma vs. COPD
Treatment Strategies in Mild to Moderate COPD
Chronic obstructive pulmonary disease
PFT Interpretation Darrin Hursey, MD.
Volume 153, Issue 4, Pages (April 2018)
Interpretation Normal Spirometry Obstructive pattern
Long-Acting Agents in Severe COPD
Gestione clinica della BPCO
Chronic Obstructive Pulmonary Disease
William P. Saliski Jr. DO Montgomery Pulmonary Consultants
Chronic Obstructive Pulmonary Disease
Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification based on symptom and risk evaluation. a) GOLD model of symptom/risk evaluation.
PALLIATIVE CARE FOR COPD PATIENTS:
Presentation transcript:

COPD Tutoring – Part 1 By Alaina Darby

How long does it take after quitting for risk of coronary heart disease to decrease by 50%? 12 hours 2 weeks 6 months 1 year 5 years

How long does it take after quitting to see improvement in lung function? 12 hours 2 weeks 6 months 1 year 5 years

Which of the following leads to emphysema? Loss of cilia Goblet cell hyperplasia Elastin destruction Mucus plugging

JR has been a smoker for 30 years and was recently diagnosed with COPD JR has been a smoker for 30 years and was recently diagnosed with COPD. Which of the following causes his pursed lip breathing? Airway inflammation due to increased mucus and protease activity Hyperinflation due to inspiratory muscle dysfunction Pulmonary hypertension due to ventilation/perfusion mismatch Decreased gas exchange due to increased airway resistance

Which of the following is least likely to be seen in JR? Macrophages Eosinophils Neutrophils CD8+ T cells

BD has smoked for 45 years. How often would you like to perform spirometry on this patient to screen for COPD? Every year Every 2 years Every 5 years Not until he has symptoms

For assessing JR, which of the following measures would you most likely use? RV TLC FVC FRC

Which of the following would be diagnostic of COPD? FEV1/FVC < 70% FEV1/FVC < 80% FVC/FEV1 < 70% FVC/FEV1 < 80%

Spirometry on TD found his FEV1/FVC to be 76% Spirometry on TD found his FEV1/FVC to be 76%. His FEV1 was 72% of predicted. What Gold class should he be placed into? I II III IV N/A

Spirometry on SD found his FEV1/FVC to be 55% Spirometry on SD found his FEV1/FVC to be 55%. His FEV1 was 72% of predicted. What Gold class should he be placed into? I II III IV N/A

Which of the following is properly matched to patient category? A: Gold III B: CAT 8 C: 3 exacerbations D: mMRC 1

Which of the following is not true of bronchodilators in COPD? Increase FEV1 Mortality benefit PRN or scheduled dosing Improve exercise performance

Spirometry on AD found her FEV1/FVC to be 45% Spirometry on AD found her FEV1/FVC to be 45%. Her FEV1 was 62% of predicted. Her CAT score is 12. What medication(s) would be most appropriate? Albuterol Salmeterol Albuterol + Ipratropium Fluticasone + Salmeterol

Which of the following causes bronchodilation through inhibition of phosphodiesterase and is a CNS stimulant? Albuterol Tiotropium Theophylline Roflumilast

VR is a 55 y/o woman with no hospital or ER insurance who has recently been diagnosed with COPD. She was placed in Gold I, has no known exacerbations, and a CAT score of 14. Which of the following is likely MOST appropriate? Albuterol Salmeterol Ipratropium Fluticasone + Salmeterol

SR is taking theophylline for her COPD SR is taking theophylline for her COPD. She has recently started having headaches, diarrhea, nausea, and dizziness. Which of the following medications may have recently be started? Phenytoin Fluvoxamine Roflumilast Carbamazapine

Which of the following patients would benefit from roflumilast? Class A patient adherent to her albuterol Class B patient nonadherent to her salmeterol Class C patient adherent to her fluticasone/salmeterol Class D patient nonadherent to her mometasone/fomoterol + ipratropium

Which of the following COPD patients should get the PCV-13? 60 y/o with FEV1 of 45% 70 y/o with FEV1 of 75% 50 y/o with FEV1 of 55% 45 y/o with FEV1 of 65%

Which of the following has been shown to decrease mortality in COPD patients? Antibiotics LABA Oxygen LAMA ICS

Which of the following would not be included in the assessment if HG was thought to be having a COPD exacerbation? Pulse oximetry Medical history EKG CBC BMP Spirometry CXR

Which of the following is the initial treatment for a COPD exacerbation? Bronchodilator Corticosteroid Oxygen Antibiotics

Which of the following would be a suitable oxygen saturation for a COPD patient undergoing an exacerbation? 86% 90% 94% 98%